RESUMEN
The mass smallpox vaccination campaign has played a crucial role in smallpox eradication. Various strains of the vaccinia virus (VACV) were used as a live smallpox vaccine in different countries, their origin being unknown in most cases. The VACV strains differ in terms of pathogenicity exhibited upon inoculation of laboratory animals and reactogenicity exhibited upon vaccination of humans. Therefore, each generated strain or clonal variant of VACV needs to be thoroughly studied in in vivo systems. The clonal variant 14 of LIVP strain (LIVP-14) was the study object in this work. A comparative analysis of the virulence and immunogenicity of LIVP-14 inoculated intranasally (i.n.), intradermally (i.d.), or subcutaneously (s.c.) to BALB/c mice at doses of 108, 107, and 106 pfu was carried out. Adult mice exhibited the highest sensitivity to the i.n. administered LIVP-14 strain, although the infection was not lethal. The i.n. inoculated LIVP-14 replicated efficiently in the lungs. Furthermore, this virus was accumulated in the brain at relatively high concentrations. Significantly lower levels of LIVP-14 were detected in the liver, kidneys, and spleen of experimental animals. No clinical manifestations of the disease were observed after i.d. or s.c. injection of LIVP-14 to mice. After s.c. inoculation, the virus was detected only at the injection site, while it could disseminate to the liver and lungs when delivered via i.d. administration. A comparative analysis of the production of virus-specific antibodies by ELISA and PRNT revealed that the highest level of antibodies was induced in i.n. inoculated mice; a lower level of antibodies was observed after i.d. administration of the virus and the lowest level after s.c. injection. Even at the lowest studied dose (106 pfu), i.n. or i.d. administered LIVP-14 completely protected mice against infection with the cowpox virus at the lethal dose. Our findings imply that, according to the ratio between such characteristics as pathogenicity/immunogenicity/protectivity, i.d. injection is the optimal method of inoculation with the VACV LIVP-14 strain to ensure the safe formation of immune defense after vaccination against orthopoxviral infections.
Asunto(s)
Anticuerpos Antivirales/sangre , Virus Vaccinia/inmunología , Virus Vaccinia/patogenicidad , Administración Intranasal , Animales , Anticuerpos Neutralizantes/sangre , Virus de la Viruela Vacuna/inmunología , Femenino , Inmunogenicidad Vacunal , Inyecciones Intradérmicas , Inyecciones Subcutáneas , Masculino , Ratones , Ratones Endogámicos BALB C , Vacuna contra Viruela , Vaccinia/prevención & control , Vaccinia/virología , Virus Vaccinia/clasificación , VirulenciaRESUMEN
Three genome sequences of Buffalopox virus (BPVX) were retrieved from a human and two buffaloes scab samples. Phylogenomic analysis of the BPXV indicates that it shares a most recent common ancestor with Lister and closely related vaccine strains when compared to potential wild-type VACV strains (like Horsepox virus).
Asunto(s)
Búfalos/virología , Genoma Viral , Filogenia , Virus Vaccinia/clasificación , Animales , Chlorocebus aethiops , ADN Viral/genética , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , India , Virus Vaccinia/aislamiento & purificación , Células Vero , Proteínas Virales/genética , Zoonosis/virologíaRESUMEN
A variety of strains of vaccinia virus (VACV) have been used as recombinant vaccine vectors with the aim of inducing robust CD8+ T cell immunity. While much of the pioneering work was done with virulent strains, such as Western Reserve (WR), attenuated strains such as modified vaccinia virus Ankara (MVA) are more realistic vectors for clinical use. To unify this literature, side-by-side comparisons of virus strains are required. Here, we compare the form of antigen that supports optimal CD8+ T cell responses for VACV strains WR and MVA using equivalent constructs. We found that for multiple antigens, minimal antigenic constructs (epitope minigenes) that prime CD8+ T cells via the direct presentation pathway elicited optimal responses from both vectors, which was surprising because this finding contradicts the prevailing view in the literature for MVA. We then went on to explore the discrepancy between current and published data for MVA, finding evidence that the expression locus and in some cases the presence of the viral thymidine kinase may influence the ability of this strain to prime optimal responses from antigens that require direct presentation. This extends our knowledge of the design parameters for VACV vectored vaccines, especially those based on MVA.IMPORTANCE Recombinant vaccines based on vaccinia virus and particularly attenuated strains such as MVA are in human clinical trials, but due to the complexity of these large vectors much remains to be understood about the design parameters that alter their immunogenicity. Previous work had found that MVA vectors should be designed to express stable protein in order to induce robust immunity by CD8+ (cytotoxic) T cells. Here, we found that the primacy of stable antigen is not generalizable to all designs of MVA and may depend where a foreign antigen is inserted into the MVA genome. This unexpected finding suggests that there is an interaction between genome location and the best form of antigen for optimal T cell priming in MVA and thus possibly other vaccine vectors. It also highlights that our understanding of antigen presentation by even the best studied of vaccine vectors remains incomplete.
Asunto(s)
Antígenos Virales/inmunología , Linfocitos T CD8-positivos/inmunología , Fragmentos de Péptidos/inmunología , Timidina Quinasa/metabolismo , Virus Vaccinia/inmunología , Vaccinia/inmunología , Vacunas Virales/inmunología , Animales , Antígenos Virales/genética , Linfocitos T CD8-positivos/metabolismo , Femenino , Genoma Viral , Inmunización , Ratones , Ratones Endogámicos C57BL , Ovalbúmina/genética , Ovalbúmina/inmunología , Timidina Quinasa/genética , Vaccinia/metabolismo , Vaccinia/virología , Virus Vaccinia/clasificación , Proteínas del Envoltorio Viral/genética , Proteínas del Envoltorio Viral/inmunología , Proteínas Virales/genética , Proteínas Virales/inmunologíaRESUMEN
Comparative examination of viral and host protein homologs reveals novel mechanisms governing downstream signaling effectors of both cellular and viral origin. The vaccinia virus B1 protein kinase is involved in promoting multiple facets of the virus life cycle and is a homolog of three conserved cellular enzymes called vaccinia virus-related kinases (VRKs). Recent evidence indicates that B1 and VRK2 mediate a common pathway that is largely uncharacterized but appears independent of previous VRK substrates. Interestingly, separate studies described a novel role for B1 in inhibiting vaccinia virus protein B12, which otherwise impedes an early event in the viral lifecycle. Herein, we characterize the B1/VRK2 signaling axis to better understand their shared functions. First, we demonstrate that vaccinia virus uniquely requires VRK2 for viral replication in the absence of B1, unlike other DNA viruses. Employing loss-of-function analysis, we demonstrate that vaccinia virus's dependence on VRK2 is only observed in the presence of B12, suggesting that B1 and VRK2 share a pathway controlling B12. Moreover, we substantiate a B1/VRK2/B12 signaling axis by examining coprecipitation of B12 by B1 and VRK2. Employing execution point analysis, we reveal that virus replication proceeds normally through early protein translation and uncoating but stalls at replication factory formation in the presence of B12 activity. Finally, structure/function analyses of B1 and VRK2 demonstrate that enzymatic activity is essential for B1 or VRK2 to inhibit B12. Together, these data provide novel insights into B1/VRK signaling coregulation and support a model in which these enzymes modulate B12 in a phosphorylation-dependent manner.IMPORTANCE Constraints placed on viral genome size require that these pathogens must employ sophisticated, yet parsimonious mechanisms to effectively integrate with host cell signaling pathways. Poxviruses are no exception and employ several methods to balance these goals, including encoding single proteins that impact multiple downstream pathways. This study focuses on the vaccinia virus B1 protein kinase, an enzyme that promotes virus replication at multiple phases of the viral lifecycle. Herein, we demonstrate that in addition to its previously characterized functions, B1 inhibits vaccinia virus B12 protein via a phosphorylation-dependent mechanism and that this function of B1 can be complemented by the cellular B1 homolog VRK2. Combined with previous data implicating functional overlap between B1 and an additional cellular B1 homolog, VRK1, these data provide evidence of how poxviruses can be multifaceted in their mimicry of cellular proteins through the consolidation of functions of both VRK1 and VRK2 within the viral B1 protein kinase.
Asunto(s)
Interacciones Huésped-Patógeno , Proteínas Serina-Treonina Quinasas/metabolismo , Virus Vaccinia/fisiología , Vaccinia/metabolismo , Vaccinia/virología , Replicación Viral , Línea Celular , Células Cultivadas , Eliminación de Gen , Técnicas de Silenciamiento del Gen , Humanos , Mutación , Fosforilación , Virus Vaccinia/clasificaciónRESUMEN
Human infections with vaccinia virus (VACV), mostly from laboratory accidents or contact with infected animals, have occurred since smallpox was eradicated in 1980. No recent cases have been reported in China. We report on an outbreak of VACV from occupational exposure to rabbit skins inoculated with VACV.
Asunto(s)
Brotes de Enfermedades , Exposición Profesional , Virus Vaccinia , Vaccinia/epidemiología , Vaccinia/virología , Accidentes de Trabajo , Adulto , Animales , China/epidemiología , Genes Virales , Historia del Siglo XXI , Humanos , Masculino , Persona de Mediana Edad , Filogenia , Conejos , Vaccinia/historia , Vaccinia/transmisión , Virus Vaccinia/clasificación , Virus Vaccinia/genética , Adulto JovenRESUMEN
The Orthopoxvirus (OPV) genus of the Poxviridae family contains several human pathogens, including Vaccinia virus (VACV), which have been implicating in outbreaks of a zoonotic disease called Bovine Vaccinia in Brazil. So far, no approved treatment exists for OPV infections, but ST-246 and Cidofovir (CDV) are now in clinical development. Therefore, the objective of this work was to evaluate the susceptibility of five strains of Brazilian VACV (Br-VACV) to ST-246 and Cidofovir. The susceptibility of these strains to both drugs was evaluated by plaque reduction assay, extracellular virus's quantification in the presence of ST-246 and one-step growth curve in cells treated with CDV. Besides that, the ORFs F13L and E9L were sequenced for searching of polymorphisms associated with drug resistance. The effective concentration of 50% (EC50) from both drugs varies significantly for different strains (from 0.0054 to 0.051⯵M for ST-246 and from 27.14 to 61.23⯵M for CDV). ST-246 strongly inhibits the production of extracellular virus for all isolates in concentrations as low as 0.1⯵M and it was observed a relevant decrease of progeny production for all Br-VACV after CDV treatment. Sequencing of the F13L and E9L ORFs showed that Br-VACV do not present the polymorphism(s) associated with resistance to ST-246 and CDV. Taken together, our results showed that ST-246 and CDV are effective against diverse, wild VACV strains and that the susceptibility of Br-VACV to these drugs mirrored the phylogenetic split of these isolates into two groups. Thus, both ST-246 and CDV are of great interest as compounds to treat individuals during Bovine Vaccinia outbreaks in Brazil.
Asunto(s)
Antivirales/farmacología , Benzamidas/farmacología , Cidofovir/farmacología , Isoindoles/farmacología , Virus Vaccinia/clasificación , Virus Vaccinia/efectos de los fármacos , Vaccinia/virología , Brasil , Humanos , Filogenia , Vaccinia/tratamiento farmacológico , Virus Vaccinia/genética , Virus Vaccinia/fisiologíaRESUMEN
Outbreaks of Vaccinia virus (VACV) affecting cattle and humans have been reported in Brazil in the last 15 years, but the origin of outbreaks remains unknown. Although VACV DNA have been already detected in mice (Mus musculus), opossums (Didelphis albiventris) and dogs during VACV zoonotic outbreaks, no transmission to cattle or humans from any of these were reported during Brazilian outbreaks. In this work, we assessed the PCR positivity to VACV in blood samples of cows and other domestic mammals, wild rodents and other wild mammals, and humans from areas with or without VACV infection reports. Our results show the detection of VACV DNA in blood samples of cows, horse and opossums, raising important questions about VACV spread.
Asunto(s)
Enfermedades de los Animales/epidemiología , Enfermedades de los Animales/virología , Animales Domésticos , Animales Salvajes , Virus Vaccinia , Vaccinia/epidemiología , Vaccinia/virología , Carga Viral , Enfermedades de los Animales/transmisión , Animales , Brasil/epidemiología , Brotes de Enfermedades , Granjas , Genes Virales , Geografía Médica , Humanos , Filogenia , Vigilancia en Salud Pública , Vaccinia/transmisión , Virus Vaccinia/clasificación , Virus Vaccinia/genética , Virus Vaccinia/aislamiento & purificaciónRESUMEN
Vaccinia virus (VACV) is a zoonotic agent that causes a disease called bovine vaccinia, which is detected mainly in milking cattle and humans in close contact with these animals. Even though many aspects of VACV infection have been described, much is still unknown about its circulation in the environment and its natural hosts/reservoirs. To investigate the presence of Orthopoxvirus antibodies or VACV DNA, we captured small rodents and marsupials in 3 areas of Minas Gerais state, Brazil, and tested their samples in a laboratory. A total of 336 animals were tested; positivity ranged from 18.1% to 25.5% in the 3 studied regions located in different biomes, including the Atlantic Forest and the Cerrado. Analysis of nucleotide sequences indicated co-circulation of VACV groups I and II. Our findings reinforce the possible role played by rodents and marsupials in VACV maintenance and its transmission chain.
Asunto(s)
Anticuerpos Antivirales/sangre , Enfermedades de los Bovinos/epidemiología , ADN Viral/sangre , Brotes de Enfermedades , Marsupiales/virología , Roedores/virología , Vaccinia/epidemiología , Animales , Brasil/epidemiología , Bovinos , Enfermedades de los Bovinos/sangre , Enfermedades de los Bovinos/transmisión , Reservorios de Enfermedades/virología , Incidencia , Tipificación Molecular , Vaccinia/sangre , Vaccinia/transmisión , Vaccinia/veterinaria , Virus Vaccinia/clasificación , Virus Vaccinia/genética , Virus Vaccinia/patogenicidadRESUMEN
Bovine vaccinia (BV), caused by Vaccinia virus (VACV), is a zoonosis characterized by exanthematous lesions on the teats of dairy cows and the milkers' hands. Since 1999, due to the occurrence of many BV outbreaks in dairy farms across all Brazilian regions, there is a need to improve the control and prevention measures of the disease. Vaccination is one of the major tools to prevent viral diseases, and it could be an alternative for BV prevention. The main objective of this study was the development of vaccine formulations against BV using the inactivated VACV strain GP2 as antigen combined with different adjuvants. Potency tests were performed in mice, which were vaccinated with two doses at a 21-day interval, and then challenged with the vaccine homologous virus. VACV strain GP2 inactivated by beta-propiolactone (BPL) in association with adjuvants was effective in inducing a humoral immune response against VACV, as measured by neutralizing antibody (NA) titers, and was variable depending on the adjuvant used in each vaccine formulation. The vaccine formulation containing aluminum hydroxide (AH) associated with saponin as adjuvant induced the production of high NA titers in all vaccinated mice, giving 100% protection in Balb/c murine model after challenge with homologous virus.
Asunto(s)
Virus Vaccinia , Vaccinia/prevención & control , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/sangre , Bovinos , Enfermedades de los Bovinos/virología , Masculino , Ratones , Ratones Endogámicos BALB C , Vacunas de Productos Inactivados , Vaccinia/virología , Virus Vaccinia/clasificación , Ensayo de Placa ViralRESUMEN
Orthopoxviruses (OPV) are emerging viruses with great importance in human and veterinary medicine, such as Vaccinia virus (VACV), which causes outbreaks of bovine vaccinia (BV) in South America. The clinical aspects of BV are similar to other vesicular infections, complicating the clinical diagnosis. This cross-sectional study evaluated the knowledge of Healthcare Professionals about BV and revealed their unpreparedness about BV in a VACV hyper-endemic area in Brazil, highlighting the public health issues associated with VACV infections. This study presents an opportunity to discuss the importance of vaccination for healthcare professionals who work in areas of VACV circulation and brings an educational measure on VACV infections for health professionals around the world.
Asunto(s)
Enfermedades Endémicas , Conocimientos, Actitudes y Práctica en Salud , Personal de Salud , Vaccinia , Adulto , Animales , Brasil/epidemiología , Bovinos , Enfermedades de los Bovinos/epidemiología , Enfermedades de los Bovinos/virología , Estudios Transversales , Enfermedades Endémicas/veterinaria , Femenino , Humanos , Masculino , Filogenia , Pruebas Serológicas , Vacunación , Vaccinia/diagnóstico , Vaccinia/epidemiología , Vaccinia/veterinaria , Virus Vaccinia/clasificación , Virus Vaccinia/genética , Virus Vaccinia/inmunología , Virus Vaccinia/aislamiento & purificación , ZoonosisRESUMEN
We investigated possible vaccinia virus (VACV) in urban house cats in Brazil. Serum samples from 6 cats were positive for VACV by PCR, indicating likely VACV circulation among house cats in urban areas of Brazil. This finding highlights the importance of epidemiologic surveillance to avoid outbreaks among urban human populations.
Asunto(s)
Enfermedades de los Gatos/epidemiología , Enfermedades de los Gatos/virología , Salud Urbana , Virus Vaccinia , Vaccinia/veterinaria , Animales , Animales Domésticos , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Brasil/epidemiología , Enfermedades de los Gatos/inmunología , Gatos , Filogenia , Vigilancia en Salud Pública , Virus Vaccinia/clasificación , Virus Vaccinia/genética , Virus Vaccinia/inmunología , Proteínas de la Matriz Viral/genética , Proteínas de la Matriz Viral/inmunologíaRESUMEN
Vaccinia virus (VACV) is the etiological agent of bovine vaccinia (BV), an emerging zoonosis that has been associated with economic losses and social effects. Despite increasing reports of BV outbreaks in Brazil, little is known about the biological interactions of Brazilian VACV (VACV-BR) isolates during coinfections; furthermore, there are no tools for the diagnosis of these coinfections. In this study, a tool to co-detect two variants of VACV was developed to provide new information regarding the pathogenesis, virulence profile, and viral spread during coinfection with VACV-BR isolates. To test the quantitative polymerase chain reactions (qPCR) tool, groups of BALB/c mice were intranasally monoinfected with Pelotas virus 1-Group II (PV1-GII) and Pelotas virus 2-Group I (PV2-GI), or were coinfected with PV1-GII and PV2-GI. Clinical signs of the mice were evaluated and the viral load in lung and spleen were detected using simultaneous polymerase chain reactions (PCR) targeting the A56R (hemagglutinin) gene of VACV. The results showed that qPCR for the quantification of viral load in coinfection was efficient and highly sensitive. Coinfected mice presented more severe disease and a higher frequency of VACV detection in lung and spleen, when compared to monoinfected groups. This study is the first description of PV1 and PV2 pathogenicity during coinfection in mice, and provides a new method to detect VACV-BR coinfections.
Asunto(s)
Enfermedades de los Bovinos/diagnóstico , Coinfección/veterinaria , Reacción en Cadena de la Polimerasa , Virus Vaccinia/fisiología , Vaccinia/veterinaria , Animales , Brasil , Bovinos , Enfermedades de los Bovinos/virología , Coinfección/diagnóstico , Coinfección/virología , Hemaglutininas Virales/genética , Masculino , Ratones , Ratones Endogámicos BALB C , Vaccinia/diagnóstico , Vaccinia/virología , Virus Vaccinia/clasificación , Virus Vaccinia/genética , Virus Vaccinia/patogenicidad , Carga Viral , VirulenciaRESUMEN
Vaccinia virus (VACV) has been implicated in infections of dairy cattle and humans, and outbreaks have substantially impacted local economies and public health in Brazil. During a 2005 outbreak, a VACV strain designated Serro 2 virus (S2V) was collected from a 30-year old male milker. Our aim was to phenotypically and genetically characterize this VACV Brazilian isolate. S2V produced small round plaques without associated comets when grown in BSC40 cells. Furthermore, S2V was less virulent than the prototype strain VACV-Western Reserve (WR) in a murine model of intradermal infection, producing a tiny lesion with virtually no surrounding inflammation. The genome of S2V was sequenced by primer walking. The coding region spans 184,572 bp and contains 211 predicted genes. Mutations in envelope genes specifically associated with small plaque phenotypes were not found in S2V; however, other alterations in amino acid sequences within these genes were identified. In addition, some immunomodulatory genes were truncated in S2V. Phylogenetic analysis using immune regulatory-related genes, besides the hemagglutinin gene, segregated the Brazilian viruses into two clusters, grouping the S2V into Brazilian VACV group 1. S2V is the first naturally-circulating human-associated VACV, with a low passage history, to be extensively genetically and phenotypically characterized.
Asunto(s)
Genoma Viral , Filogenia , Análisis de Secuencia de ADN , Virus Vaccinia/genética , Virus Vaccinia/aislamiento & purificación , Vaccinia/virología , Adulto , Animales , Brasil , Línea Celular , Modelos Animales de Enfermedad , Genes Virales , Humanos , Masculino , Ratones , Homología de Secuencia , Vaccinia/patología , Virus Vaccinia/clasificación , Virus Vaccinia/fisiología , Ensayo de Placa Viral , Virulencia , Factores de Virulencia/genéticaRESUMEN
We detected orthopoxvirus in 28 of 125 serum samples collected during 2009 from cattle in Uruguay. Two samples were PCR-positive for vaccinia virus and had sequences similar to those for vaccinia virus associated with outbreaks in Brazil. Autochthonous circulation of vaccinia virus in Uruguay and other South American countries cannot be ruled out.
Asunto(s)
Enfermedades de los Bovinos/epidemiología , Enfermedades de los Bovinos/virología , Virus Vaccinia/genética , Vaccinia/veterinaria , Animales , Bovinos , Brotes de Enfermedades , Genes Virales , Geografía Médica , ARN Viral , América del Sur/epidemiología , Uruguay/epidemiología , Virus Vaccinia/clasificación , Virus Vaccinia/aislamiento & purificación , ZoonosisRESUMEN
During a vaccinia virus (VACV) outbreak in São Paulo State, Brazil, blood samples were collected from cows, humans, other domestic animals, and wild mammals. Samples from 3 dogs and 3 opossums were positive for VACV by PCR. Results of gene sequencing yielded major questions regarding other mammalian species acting as reservoirs of VACV.
Asunto(s)
Enfermedades de los Bovinos/epidemiología , Enfermedades de los Bovinos/virología , Brotes de Enfermedades , Virus Vaccinia/genética , Vaccinia/epidemiología , Vaccinia/virología , Animales , Brasil/epidemiología , Bovinos , Perros , Genes Virales , Humanos , Zarigüeyas , Filogenia , Vaccinia/diagnóstico , Virus Vaccinia/clasificaciónRESUMEN
Buffalopox is a contagious viral disease affecting milch buffaloes (Bubalus Bubalis) and, rarely, cows. The disease has zoonotic implications, as outbreaks are frequently associated with human infections, particularly in the milkers. Buffalopox is associated with high morbidity (80%). The clinical symptoms of the disease are characterized by wartline lesions on the udder, teats, inguinal region, base of the ears, and over the parotid. In the severe form, generalized rash is observed. Although the disease does not lead to high mortality, it has an adverse effect on the productivity and working capacity of the animals resulting in large economic losses. The outbreaks of buffalopox occurred frequently in India, Pakistan, Bangladesh, Nepal, Iran, Egypt, and Indonesia, where buffaloes are reared as milch animals. The buffalopox is closely related with other Orthopoxviruses. In particular, it is close to the vaccinia virus. There is a view that the buffalopox virus might be derived from the vaccinia virus. It is possible that it became pathogenic to humans and animals through adaptive evolution of the genome by obtaining the virulence genes. PCR is performed for the C18L gene for the purpose of specific detection and differentiation of the buffalopox virus from other orthopoxviruses. The C18L gene encodes the ankyrin repeat protein, which determines the virus host range. The open reading frame of this gene is only 150-nucleotide long as against 453 nucleotide in the vaccinia virus, 756 - in the camelpox virus, and 759 - in the cowpox virus. It can be concluded that a systematic study based on the epidemiology of the virus, existence of reservoirs, biological transmission, and the molecular organization of the buffalopox virus from buffalo, cow, and humans may pave the way to a better understanding of the circulating virus and contribute to the control of the disease using the suitable diagnostic and prophylactic measures.
Asunto(s)
Virus de la Viruela Vacuna/genética , Viruela Vacuna/epidemiología , Brotes de Enfermedades , Virus Vaccinia/genética , Vaccinia/veterinaria , Zoonosis/epidemiología , Animales , Repetición de Anquirina , Asia Occidental/epidemiología , Búfalos/virología , Bovinos , Viruela Vacuna/transmisión , Viruela Vacuna/virología , Virus de la Viruela Vacuna/clasificación , Virus de la Viruela Vacuna/aislamiento & purificación , ADN Viral/genética , Medio Oriente/epidemiología , Filogenia , Vaccinia/epidemiología , Vaccinia/transmisión , Vaccinia/virología , Virus Vaccinia/clasificación , Virus Vaccinia/aislamiento & purificación , Proteínas Virales/genética , Zoonosis/transmisión , Zoonosis/virologíaRESUMEN
Vaccinia virus (VACV), the etiological agent of bovine vaccinia (BV), is widespread in Brazil and present in most of the milk-producing regions. We conducted a horizontal study of BV in Bahia, a state of Brazil in which the production of milk is increasing. During 2011, human and bovine clinical samples were collected during outbreaks for BV diagnosis, virus isolation and molecular analysis. We collected data for epidemiological inferences. Vaccinia virus was detected in 87.7% of the analyzed outbreaks, highlighting the effective circulation of VACV in Bahia. The molecular data showed the spreading of group 1 Brazilian VACV to Bahia. We observed a seasonal profile of BV, with its peak in the drier and cooler season. Manual milking was observed in 96 % of the visited properties, showing its importance to viral spread in herds. Under-notification of BV, ineffective animal trade surveillance, and bad milking practices have contributed to the spread of VACV in Brazil.
Asunto(s)
Enfermedades de los Bovinos/virología , Filogenia , Virus Vaccinia/clasificación , Virus Vaccinia/aislamiento & purificación , Vaccinia/veterinaria , Vaccinia/virología , Animales , Brasil , Bovinos , Enfermedades de los Bovinos/economía , Enfermedades de los Bovinos/epidemiología , Enfermedades de los Bovinos/transmisión , Brotes de Enfermedades/economía , Humanos , Vaccinia/economía , Vaccinia/epidemiología , Vaccinia/transmisión , Virus Vaccinia/genética , Zoonosis/economía , Zoonosis/epidemiología , Zoonosis/transmisión , Zoonosis/virologíaRESUMEN
CD8(+) T cells that recognize virus-derived peptides presented on MHC class I are vital antiviral effectors. Such peptides presented by any given virus vary greatly in immunogenicity, allowing them to be ranked in an immunodominance hierarchy. However, the full range of parameters that determine immunodominance and the underlying mechanisms remain unknown. In this study, we show across a range of vaccinia virus strains, including the current clonal smallpox vaccine, that the ability of a strain to spread systemically correlated with reduced immunodominance. Reduction in immunodominance was observed both in the lymphoid system and at the primary site of infection. Mechanistically, reduced immunodominance was associated with more robust priming and especially priming in the spleen. Finally, we show this is not just a property of vaccine and laboratory strains of virus, because an association between virulence and immunodominance was also observed in isolates from an outbreak of zoonotic vaccinia virus that occurred in Brazil.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Vacuna contra Viruela/inmunología , Virus Vaccinia/inmunología , Vaccinia/inmunología , Secuencia de Aminoácidos , Animales , Antígenos Virales/inmunología , Linfocitos T CD8-positivos/metabolismo , Linfocitos T CD8-positivos/virología , Línea Celular , Epítopos de Linfocito T/inmunología , Femenino , Interacciones Huésped-Patógeno/inmunología , Epítopos Inmunodominantes/inmunología , Interferón gamma/inmunología , Interferón gamma/metabolismo , Ratones Endogámicos C57BL , Especificidad de la Especie , Bazo/inmunología , Bazo/metabolismo , Bazo/virología , Vaccinia/virología , Virus Vaccinia/clasificación , Virus Vaccinia/fisiología , Zoonosis/virologíaRESUMEN
Vaccinia virus (VACV) has had an important role for humanity because of its use during the smallpox eradication campaign. VACV is the etiologic agent of the bovine vaccinia (BV), an emerging zoonosis that has been associated with economic, social, veterinary and public health problems, mainly in Brazil and India. Despite the current and historical VACV importance, there is little information about its circulation, prevalence, origins and maintenance in the environment, natural reservoirs and diversity. Brazilian VACV (VACV-BR) are grouped into at least two groups based on genetic and biological diversity: group 1 (G1) and group 2 (G2). In this study, we went to the field and investigated VACV clonal diversity directly from exanthemous lesions, during BV outbreaks. Our results demonstrate that the G1 VACV-BR were more frequently isolated. Furthermore, we were able to co-detect the two variants (G1 and G2) in the same sample. Molecular and biological analysis corroborated previous reports and confirmed the co-circulation of two VACV-BR lineages. The detected G2 clones presented exclusive genetic and biological markers, distinct to reference isolates, including VACV-Western Reserve. Two clones presented a mosaic profile, with both G1 and G2 features based on the molecular analysis of A56R, A26L and C23L genes. Indeed, some SNPs and INDELs in A56R nucleotide sequences were observed among clones of the same virus population, maybe as a result of an increased mutation rate in a mixed population. These results provide information about the diversity profile in VACV populations, highlighting its importance to VACV evolution and maintenance in the environment.
Asunto(s)
Viruela Vacuna/virología , Variación Genética , Virus Vaccinia/clasificación , Virus Vaccinia/genética , Animales , Peso Corporal , Brasil/epidemiología , Bovinos , Viruela Vacuna/epidemiología , Viruela Vacuna/patología , Modelos Animales de Enfermedad , Genotipo , Masculino , Ratones Endogámicos BALB C , Epidemiología Molecular , Datos de Secuencia Molecular , Análisis de Secuencia de ADN , Homología de Secuencia , Virus Vaccinia/aislamiento & purificación , VirulenciaRESUMEN
In 2010, a vaccinia virus isolate caused an atypically severe outbreak that affected humans and cattle in Brazil. Of 26 rural workers affected, 12 were hospitalized. Our data raise questions about the risk factors related to the increasing number and severity of vaccinia virus infections.